Hydrogen sulfide (H 2 S) is an endogenous gaseous biological mediator. In the cardiovascular system, it acts as a vasodilator, proangiogenic hormone, and cardioprotectant, while in the nervous system, it functions as a neurotransmitter and neuroprotectant. 1, 2 Our interest in the role of H 2 S in cancer biology was initially triggered by our observations in endothelial cells showing that the proangiogenic effect of VEGF (vascular endothelial growth factor, a principal tumor angiogenic hormone) is mediated in part by endogenous H 2 S. 3 VEGF increased H 2 S production in endothelial cells, and inhibition of CSE (cystathionine gamma-lyase, a major H 2 S-producing enzyme) attenuated the proangiogenic effects of VEGF in vitro. 3 Our original hypothesis was that cancer cell-derived VEGF stimulates tumor angiogenesis via stimulation of H 2 S production in peritumoral tissues.
While experimentally testing this hypothesis, we have discovered that colorectal cancer tissue from human surgical resections contains markedly elevated levels of a different H 2 Sproducing enzyme, cystathionine-β-synthase (CBS). 4 Likewise, the colon cancer-derived epithelial cell lines HCT116, HT-29, and LoVo contained high levels of CBS when compared with a non-malignant colonic mucosal cell line (NCM356). In contrast to CBS, no cancerspecific differences could be detected in the expression of CSE, or the third H 2 Sproducing enzyme, 3-mercaptopyruvate sulfurtransferase . The marked and selective upregulation of CBS in tumor cells induced us to re-focus on the functional role of this enzyme in cancer. shRNA-mediated silencing of CBS significantly reduced HCT116 cell H 2 S production, proliferation, migration, and invasion and attenuated endothelial cell migration in tumor/endothelial cell co-cultures in vitro. 4 Subsequent studies in nude mice bearing subcutaneous tumor xenografts of HCT116 cells with stable lentiviral silencing of CBS exhibited a reduced rate of tumor growth compared with control HCT116 cells. 4 Furthermore, CBS silencing in cancer cells reduced intratumoral neovessel density, suggesting that H 2 S diffuses out from the tumor cell to stimulated tumor angiogenesis. The effects of CBS silencing were recapitulated with the pharmacological CBS inhibitor aminooxyacetic acid (AOAA) both in vitro and in vivo. 4 Moreover, treatment of nude mice with AOAA attenuated the growth of patient-derived colon cancer xenografts and reduced peritumoral blood flow. 4 Based on the above data we have formulated a new concept, which implicates tumor-produced CBS-derived H 2 S as a combined autocrine and paracrine-signaling molecule (Fig. 1) . As an autocrine factor, H 2 S stimulates growth, proliferation, and migration of the colorectal cancer cell, while as a paracrine factor it promotes tumor angiogenesis and peritumoral vasodilation.
In contrast to CBS, our data showed that silencing of CSE or its inhibition with propargylglycine (PAG) does not inhibit the growth of HCT116 cells. 4 Thus, CBS, and not CSE is the relevant source of endogenous, tumor cellproduced H 2 S. While the potential role of endothelial-produced, CSE-derived H 2 S in tumor angiogenesis requires further investigation, our in vivo data in the nude mice showing that the CSE inhibitor PAG does not inhibit tumor growth 4 suggest that CSE-derived H 2 S does not play a major role (at least in colorectal cancers). We hypothesize that this may be due to the fact that, due to the massive upregulation of CBS in the tumor tissue-the peritumor vasculature is already in a "cloud" of H 2 S; if the endothelial cells are already exposed to high amounts of H 2 S produced by the tumor tissue, than supplemental, intraendothelial production of H 2 S may only have a minor effect on endothelial cell H 2 S homeostasis.
What are the molecular mechanisms by which the CBS/H 2 S axis stimulates the growth, proliferation, and migration of colorectal cancer cells? With regard to cancer cell proliferation, one mechanism is related to the role of H 2 S as a bioenergetic factor. Recent data demonstrate that H 2 S, at relatively low concentrations, acts as a mitochondrial electron donor, which works in concert with the "classical" Krebs-cycle-derived electron donors. 5, 6 A separate line of studies identified H 2 S as an activator the glycolytic enzyme GAPH via sulfhydration. 7 In line with these findings, we showed that silencing of CBS and inhibition of cell proliferation is associated with an attenuation of both oxidative phosphorylation and glycolysis in HCT116 cells. 4 Another mechanism may be related to a H 2 S-mediated activation of PI3K: An independent line of studies in HCT116 cells demonstrates that H 2 S is a potent activator of the PI3K pathway;
8 it also regulates cell cycle via the phosphorylation of cell cycle kinase inhibitor p21CIP.
8 While the precise department of anesthesiology; university of texas Medical Branch; Galveston, tX usa; 2 department of surgery; university of texas Medical Branch; Galveston, tX usa molecular relationship between these pathways remains to be delineated, it is conceivable that the energetic and signaling responses act in functional synergy for tumor cell movement by providing "direction" (the PI3K pathway contributes to cell polarity and guides the direction of migration) and "fuel" (ATP, to help in the "execution" of the process), respectively. Taken together, CBS-derived H 2 S emerges as a novel endogenous tumor cell-derived growth and survival factor. Further work will determine whether small-molecule CBS inhibitors (on their own, or perhaps in an appropriately chosen combination with other anticancer drugs) can be of utility as anticancer agents. In order to identify the most effective combinations, the relationship of H 2 S-mediated pathways with "traditional" bioenergetic and signaling pathways needs to be characterized in detail. When considering the translational aspects of our discovery, the physiological roles of CBS (including homocysteine metabolism and the regulation of neurotransmission), and the potential adverse consequences of its pharmacological inhibition need to be taken into account as well.
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